| Literature DB >> 34224834 |
Dongguang Wang1, Lingmin Chen2, Lian Wang1, Fang Hua3, Juan Li4, Yuxi Li4, Yonggang Zhang5, Hong Fan6, Weimin Li7, Mike Clarke8.
Abstract
OBJECTIVES: To assess the reporting quality of abstracts for published randomized controlled trials (RCTs) of interventions for coronavirus disease 2019 (COVID-19), including the use of spin strategies and the level of spin for RCTs with statistically non-significant primary outcomes, and to explore potential predictors for reporting quality and the severity of spin. STUDY DESIGN ANDEntities:
Keywords: CONSORT: consolidated standards of reporting trials; COVID-19: coronavirus disease 2019; IQR: interquartile range; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; abstract, COVID-19, randomized controlled trial, primary outcome, reporting quality, spin Abbreviations RCT: randomized controlled trial
Year: 2021 PMID: 34224834 PMCID: PMC8253697 DOI: 10.1016/j.jclinepi.2021.06.027
Source DB: PubMed Journal: J Clin Epidemiol ISSN: 0895-4356 Impact factor: 6.437
Fig. 1Flow diagram for trial selections.
General characteristics of the 40 RCTs related to COVID-19.
| Characteristic | Category | N (%) |
| Journal type | Specialized medicine | 23 (57.5) |
| General medicine | 17 (42.5) | |
| Average journal impact factor in recent five years, median( [IQR]) | 4.858 (2.735, 40.063) | |
| Geographical location | Asia | 26 (65.0) |
| Europe | 7 (17.5) | |
| America | 6 (15.0) | |
| Africa | 1 (2.5) | |
| No. of authors | ≤7 | 6 (15.0) |
| >7 | 34 (85.0) | |
| Type of institution | University | 31 (77.5) |
| Others | 9 (22.5) | |
| Centers | Single center | 18 (45.0) |
| Multicenter | 22 (55.0) | |
| Word count in the abstract | <200 | 2 (5.0) |
| 200-400 | 28 (70.0) | |
| >400 | 10 (25.0) | |
| Objective | Efficacy | 20 (50.0) |
| Safety | 0 (0) | |
| Efficacy and safety | 20 (50.0) | |
| Structured format in the abstract | Yes | 33 (82.5) |
| No | 7 (17.5) | |
| Sample size | <50 | 10 (25.0) |
| 50-100 | 13 (32.5) | |
| >100 | 17 (42.5) | |
| Intervention | Drugs | 33 (82.5) |
| Nonpharmaceutical interventions | 7 (17.5) | |
| Treatment arms | 2 | 33 (82.5) |
| >2 | 7 (17.5) | |
| Primary outcomes | 1 | 26 (65.0) |
| >1 | 14 (35.0) | |
| Exact P value | Yes | 28 (70.0) |
| No | 12 (30.0) | |
| Funding source | None | 2 (5.0) |
| Industry | 5 (12.5) | |
| Nonindustry | 21 (52.5) | |
| Industry and nonindustry | 6 (15.0) | |
| Not reported | 6 (15.0) | |
| Total | 40(100.0) |
IQR, interquartile range.
Fig. 2Bar graph of the reporting quality of forty RCT abstracts based on the sixteen-item CONSORT statement for abstracts.
Reporting of each item and subitem in forty RCT abstracts based on the CONSORT 2010 explanation and elaboration for abstracts.
| Item | Criteria and subitems | N (%) |
| 1. Title | Identification of the study as randomized in the title. | 33 (82.5) |
| 2. Trial design | Structured summary of the trial design (eg, parallel, cluster, crossover). | 2 (5.0) |
| 3. Participants | Eligibility criteria for participants and settings or locations where the data were collected. | 20 (50.0) |
| 3a. Eligibility criteria for participants. | 29 (72.5) | |
| 3b. Settings or locations for data collections. | 22 (55.0) | |
| 4. Interventions | Sufficient details of interventions intended for each group (eg, when, how). | 25 (62.5) |
| 5. Objectives | Specific objectives or hypotheses. | 32 (80.0) |
| 6. Primary outcomes | Clearly defined primary outcomes for this trial in methods. | 28 (70.0) |
| 7. Randomization | Scientific descriptions of how participants were allocated to interventions. | 1 (2.5) |
| 7a. Random assignment (eg, random, randomized, randomization, random allocation). | 37 (92.5) | |
| 7b. Sequence generation (eg, random-number tables). | 2(5.0) | |
| 7c. Referring to allocation concealment. | 1 (2.5) | |
| 8. Blinding(masking) | Whether or not participants, trial providers, and data collectors were blinded. | 1 (2.5) |
| 8a. Brief descriptions only (eg, single-blind, double-blind, triple-blind). | 9 (22.5) | |
| 9. Numbers randomized | Numbers of participants randomized to each group. | 32 (80.0) |
| 10. Recruitment and following up | Trial status (eg, on-going, closed to recruitment, closed to follow-up). | 1 (2.5) |
| 11. Numbers analyzed | Numbers of participants analyzed in each group. | 32 (80.0) |
| 11a. Whether or not analyzed in accordance with the original grouping (eg, intention-to-treat analysis or pre-protocol analysis). | 4 (10.0) | |
| 12. Reports of primary outcomes | For the primary outcomes, a summary report of results for each group and the estimated effect size and its precision. | 10 (25.0) |
| 12a. Primary outcome results for each group. | 20 (50.0) | |
| 12b. Estimated effect size. | 17 (42.5) | |
| 12c. Precision of the estimate (eg, 95%CI). | 16 (40.0) | |
| 13. Harms | Important adverse events or side effects (seeing CONSORT for harms for specific guidance). | 21 (52.5) |
| 14. Conclusions | General interpretations corresponding to the results. | 39 (97.5) |
| 14a. Benefits and harms balanced. | 20 (50.0) | |
| 15. Trial registration | Trial registration number and the name of trial register. | 28 (70.0) |
| 16. Funding and supports | Source of funding and supports. | 10 (25.0) |
Fig. 3Factors associated with overall reporting score in forty RCT abstracts.
aFor the multivariate linear regression analyses, adjusted R² = 0.467, P < 0.001.
bP < 0.05 was considered statistically significant, shown in bold.
Abbreviations: IF, impact factor; CI, confidence interval.
Spin strategies identified in 16 RCT abstracts with spin
| N (%) | |
| Spin strategies in the result section | |
| Focusing on statistically significant within-group comparisons. | 2 (12.5) |
| Focusing on statistically significant secondary outcomes. | 12 (75.0) |
| Focusing on statistically significant subgroup analyses. | 4 (25.0) |
| Focusing on statistically significant within- or between-group comparisons of secondary outcomes. | 1 (6.3) |
| Focusing only on primary outcome of statistical significance when several primary outcomes exist. | 3 (18.8) |
| Spin strategies in the conclusion section | |
| Claiming equivalent/noninferior/comparable/similar effects for statistically nonsignificant primary endpoints. | 0 (0) |
| Focusing only on statistically significant results (eg, secondary outcomes, subgroup analyses, within-group analyses). | 4 (25.0) |
| Claiming benefit with no consideration of the statistically nonsignificant primary outcomes. | 12 (75.0) |
| Recommendation to use the experimental treatment. | 5 (31.3) |
| Focusing only on outcomes with statistical significance when several primary outcomes exist. | 3 (18.8) |
| Focusing only on time-points with statistical significance when multiple time-points for primary outcomes exist. | 0 (0) |
Assessment of level of spin in the conclusion section of RCT abstracts
| Level of spin in the conclusion section | N (%) |
| Low | 3 (25.0) |
| Moderate | 3 (25.0) |
| High | 6 (50.0) |
Acknowledge statistically nonsignificant results for the primary outcome, or no acknowledgment of statistically nonsignificant results for the primary outcome but reported with uncertainty and recommendations for further trials.
No acknowledgment of statistically nonsignificant results for the primary outcome but reported with uncertainty or recommendations for further trials.
No acknowledgment of statistically nonsignificant results for the primary outcome, no uncertainty and no recommendations for further trials.
Fig. 4Factors related to spin severity in 27 RCT abstracts with statistically nonsignificant primary outcomes.
aFor the multivariate linear regression analyses, adjusted R²=0.388, P = 0.002.
bP < 0.05 was considered statistically significant, shown in bold.
Abbreviations: IF, impact factor; CI, confidence interval.